The California Institute for Regenerative Medicine (CIRM) recently awarded $1.5 million to Denise Al Alam, PhD, of the Lundquist Institute to study lung disease in people with Trisomy 21, or Down syndrome.
Although Trisomy 21 affects many organs, respiratory complications are a leading cause of death in children and adults. Dr. Al Alam’s project will use patient‑derived pluripotent stem cells from diverse backgrounds to model alveolar defects linked to Trisomy 21.
The study will generate new Trisomy 21 cell lines and identify genes and pathways tied to these defects. This work may guide future targeted therapies.
In California, about 667 babies are born with Down syndrome each year, with the highest rate among Latinx infants.
“Respiratory complications cause major mortality in children and adults with Down syndrome. We are thrilled to support research that deepens our understanding of lung disease in this population,” said Dr. Canet‑Avilés.
Understanding lung disease in Trisomy 21 is essential to improving outcomes. This innovative project could lead to targeted therapies and better quality of life for affected individuals.
Related posts
• UCSD researchers use stem cell model to better understand pregnancy complications
It’s encouraging to see such a significant investment in research focused on lung disease in individuals with Down Syndrome. Understanding and addressing the respiratory complications associated with Trisomy 21 could indeed improve life expectancy and quality of life for those affected. This project not only highlights the potential for targeted therapies but also emphasizes the importance of inclusivity in medical research.